Co-mutations in tumor immune microenvironment and immunotherapy

被引：3
作者：
Ma, Ling [1 ]
Zhu, Ling-Jun [1 ]
Xu, Zi-Jie [1 ]
Shu, Yong-Qian [1 ]
机构：
[1] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2021年 / 134卷 / 09期
基金：
中国国家自然科学基金;
关键词：
COOCCURRING GENOMIC ALTERATIONS; LUNG ADENOCARCINOMA; CANCER; EXPRESSION; BIOLOGY; P53;
D O I：
10.1097/CM9.0000000000001455
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1055 / 1057
页数：3
相关论文
共 16 条
  • [1] Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
    Alspach, Elise
    Lussier, Danielle M.
    Schreiber, Robert D.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2019, 11 (03):
  • [2] Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
    Arbour, Kathryn C.
    Jordan, Emmett
    Kim, Hyunjae Ryan
    Dienstag, Jordan
    Yu, Helena A.
    Sanchez-Vega, Francisco
    Lito, Piro
    Berger, Michael
    Solit, David B.
    Hellmann, Matthew
    Kris, Mark G.
    Rudin, Charles M.
    Ni, Ai
    Arcila, Maria
    Ladanyi, Marc
    Riely, Gregory J.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (02) : 334 - 340
  • [3] Targeting mutant p53 for efficient cancer therapy
    Bykov, Vladimir J. N.
    Eriksson, Sofi E.
    Bianchi, Julie
    Wiman, Klas G.
    [J]. NATURE REVIEWS CANCER, 2018, 18 (02) : 89 - 102
  • [4] Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
    Calles, Antonio
    Sholl, Lynette M.
    Rodig, Scott J.
    Pelton, Ashley K.
    Hornick, Jason L.
    Butaney, Mohit
    Lydon, Christine
    Dahlberg, Suzanne E.
    Oxnard, Geoffrey R.
    Jackman, David M.
    Jaenne, Pasi A.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2851 - 2860
  • [5] Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
    Cha, Yoon Jin
    Kim, Hye Ryun
    Lee, Chang Young
    Cho, Byoung Chul
    Shim, Hyo Sup
    [J]. LUNG CANCER, 2016, 97 : 73 - 80
  • [6] Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
    Dong, Zhong-Yi
    Zhong, Wen-Zhao
    Zhang, Xu-Chao
    Su, Jian
    Xie, Zhi
    Liu, Si-Yang
    Tu, Hai-Yan
    Chen, Hua-Jun
    Sun, Yue-Li
    Zhou, Qing
    Yang, Jin-Ji
    Yang, Xue-Ning
    Lin, Jia-Xin
    Yan, Hong-Hong
    Zhai, Hao-Ran
    Yan, Li-Xu
    Liao, Ri-Qiang
    Wu, Si-Pei
    Wu, Yi-Long
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (12) : 3012 - 3024
  • [7] Expression of tumour-specific antigens underlies cancer immunoediting
    DuPage, Michel
    Mazumdar, Claire
    Schmidt, Leah M.
    Cheung, Ann F.
    Jacks, Tyler
    [J]. NATURE, 2012, 482 (7385) : 405 - U1512
  • [8] Adaptive immunity maintains occult cancer in an equilibrium state
    Koebel, Catherine M.
    Vermi, William
    Swann, Jeremy B.
    Zerafa, Nadeen
    Rodig, Scott J.
    Old, Lloyd J.
    Smyth, Mark J.
    Schreiber, Robert D.
    [J]. NATURE, 2007, 450 (7171) : 903 - U24
  • [9] STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
    Koyama, Shohei
    Akbay, Esra A.
    Li, Yvonne Y.
    Aref, Amir R.
    Skoulidis, Ferdinandos
    Herter-Sprie, Grit S.
    Buczkowski, Kevin A.
    Liu, Yan
    Awad, Mark M.
    Denning, Warren L.
    Diao, Lixia
    Wang, Jing
    Parra-Cuentas, Edwin R.
    Wistuba, Ignacio I.
    Soucheray, Margaret
    Tran Thai
    Asahina, Hajime
    Kitajima, Shunsuke
    Altabef, Abigail
    Cavanaugh, Jillian D.
    Rhee, Kevin
    Gao, Peng
    Zhang, Haikuo
    Fecci, Peter E.
    Shimamura, Takeshi
    Hellmann, Matthew D.
    Heymach, John V.
    Hodi, F. Stephen
    Freeman, Gordon J.
    Barbie, David A.
    Dranoff, Glenn
    Hammerman, Peter S.
    Wong, Kwok-Kin
    [J]. CANCER RESEARCH, 2016, 76 (05) : 999 - 1008
  • [10] Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
    Kron, A.
    Alidousty, C.
    Scheffler, M.
    Merkelbach-Bruse, S.
    Seidel, D.
    Riedel, R.
    Ihle, M. A.
    Michels, S.
    Nogova, L.
    Fassunke, J.
    Heydt, C.
    Kron, F.
    Ueckeroth, F.
    Serke, M.
    Krueger, S.
    Grohe, C.
    Koschel, D.
    Benedikter, J.
    Kaminsky, B.
    Schaaf, B.
    Braess, J.
    Sebastian, M.
    Kambartel, K. -O.
    Thomas, R.
    Zander, T.
    Schultheis, A. M.
    Buettner, R.
    Wolf, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (10) : 2068 - 2075
12